Chondrosarcoma: Multi-Targeting Therapeutic Effects of Doxorubicin, BEZ235, and the Small Molecule Aspartyl-Asparaginyl-β-hydroxylase Inhibitor SMI1182
Triple-drug treatment with DOX, SMI1182, and BEZ235 could potentially improve disease-free survival with CS by the simultaneous targeting of multiple upstream mediators of aggressive malignant tumor cell behavior.
Authors
- Suzanne M. de la Monte (ORCID: https://orcid.org/0000-0001-5886-2306)
- Rolf I. Carlson (ORCID: https://orcid.org/0000-0002-6965-8754)
- René Rodrı́guez (ORCID: https://orcid.org/0000-0002-0768-7306)
- Bhaskar C. Das (ORCID: https://orcid.org/0000-0002-5837-027X)
- Megan Fife
- C. Parthiban (ORCID: https://orcid.org/0000-0003-0763-8237)
- Ming Tong (ORCID: https://orcid.org/0000-0002-4532-5269)
Institutions
- Brown University (US)
- Rhode Island Hospital (US)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Instituto de Investigación Sanitaria del Principado de Asturias (ES)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3390/cancers17101671
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Alcohol Abuse and Alcoholism